AI tools very rarely work as out-of-the box solutions, noted Zafar Chaudry, chief digital officer and chief AI and information officer at Seattle Children’s. When hospitals enter into contracts with AI developers to build tools that are the right fit, he thinks the two parties should share risk. That way, hospitals won’t be stuck paying…
Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date. The post Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity appeared first on…
By reducing the time spent on administrative tasks, AI scribes allow physicians to focus more on what truly matters — patient care. As the technology continues to evolve and improve, its adoption will likely become more widespread, further enhancing its benefits. The post Evidence-Based Medicine: AI Scribes Actually Work appeared first on MedCity News.
I asked if I could purchase the brace myself and bring it to the surgery. The answer was an unequivocal no: the health insurer’s contracted rate required me to purchase the brace from the hospital as part of the procedure. The post A 2,100% Markup: My Battle with a Vastly Overpriced Knee Brace — and…
Charity Tarn, an investor with Arboretum Ventures, will be one of the investor judges for the Pitch Perfect contest at INVEST in Chicago May 20-21. Register today! The post Arboretum Ventures Investor Says Startups Are Adapting to Tough Healthcare Fundraising Environment appeared first on MedCity News.
Abarca Health is paying attention to specialty drugs, AI in healthcare, the impact of obesity-related conditions, and increased government regulations. The post 4 Prescription Drug Trends that are Top of Mind for One Abarca Exec appeared first on MedCity News.
Many experts – be they venture capitalists or private equity investprs – shared their advice to biotech entrepreneurs navigating a tough funding envornment. The post How Can Startups Navigate the Difficult Funding Environment appeared first on MedCity News.
Some healthcare providers have partnered with AI gun detection company ZeroEyes. The company adds its software to hospitals’ existing security camera systems to identify a gun before the shooter strikes. The post How One AI Company Is Tackling Gun Violence at Hospitals appeared first on MedCity News.
Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio in 2021. 2seventy and Bristol Myers Squibb currently share in U.S. commercialization of Abecma. The post Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal appeared first on MedCity News.
As healthcare leaders look for the low-hanging fruit for AI and automation investments in the revenue cycle, there are three things that should be considered to achieve maximum impact on labor effectiveness. The post Revenue Cycle Automation: 3 Considerations For Optimal ROI appeared first on MedCity News.